Daily DigestInterMune announces EAP for pirfenidone to treat Idiopathic Pulmonary Fibrosis …Pharmaceutical Business ReviewUS-based biotechnology firm InterMune will provide compassionate use of pirfenidone through a multi-center Expanded Access Program (EAP) in the US to be carried out under its US Investigational New Drug (IND) application for the treatment of Idiopathic …Study Shows No Benefit from Widely Used Antioxidant in Treating Deadly Lung …Cornell ChronicleNintedanib shown to slow progression of fatal lung diseaseDaily DigestInterMune: Good Data Goes a Long WayBarron’s (blog)FierceBiotech -Food Consumer -Daily Echoall 51 news articles …Read Full Story
InterMune announces EAP for pirfenidone to treat Idiopathic Pulmonary Fibrosis ... - Pharmaceutical Business Review
Real Estate of Cebu
